Filtros de búsqueda

Lista de obras de William C. Gruber

1098The Immunogenicity of PCV13 compared to PPSV23 in Immunocompetent Older Adults with Stable High Risk Conditions.

artículo científico publicado en 2014

13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial

artículo científico publicado en 2013

13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccine

artículo científico publicado en 2014

13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants.

artículo científico publicado en 2015

13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study

artículo científico publicado en 2015

13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety

artículo científico publicado en 2012

2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate

2781. Statistical Modeling to Predict Maternal RSV Vaccine Efficacy from Neutralizing Titers

A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 Years

artículo científico publicado en 2020

A clinical trial examining the effect of increased total CRM197 carrier protein dose on the antibody response to Haemophilus influenzae type b CRM197 conjugate vaccine

article

A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children

artículo científico publicado en 2009

A phase 1 randomized study assessing safety and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy older Japanese adults

scientific article published on 05 April 2019

A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults

artículo científico publicado en 2016

A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil

artículo científico publicado en 2012

A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands

artículo científico publicado en 2019

A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older

artículo científico

A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults.

artículo científico

A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations

artículo científico

A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults

artículo científico publicado en 2021

A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine

artículo científico publicado en 2006

An open-label randomized clinical trial of prophylactic paracetamol coadministered with 7-valent pneumococcal conjugate vaccine and hexavalent diphtheria toxoid, tetanus toxoid, 3-component acellular pertussis, hepatitis B, inactivated poliovirus, a

artículo científico publicado en 2013

Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccine

artículo científico publicado en 2013

Carrier-Induced Hyporesponsiveness to Pneumococcal Conjugate Vaccines: The Influence of Serotypes, Timing, and Previous Vaccine Dose Unraveled

scientific article published on 29 January 2020

Circulating Antibody 1 and 2 Years After Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine in Preterm Compared With Term Infants.

artículo científico publicado en 2016

Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial

article

Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial

artículo científico publicado en 2013

Comparison of results of detection of rhinovirus by PCR and viral culture in human nasal wash specimens from subjects with and without clinical symptoms of respiratory illness

artículo científico publicado en 2007

Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma

artículo científico publicado en 2006

Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children

artículo científico publicado en 2008

Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine

artículo científico publicado en 2012

Diagnostic accuracy of a serotype-specific antigen test in community-acquired pneumonia

artículo científico publicado en 2013

Effectiveness of 13-valent pneumococcal conjugate vaccination for protection against acute otitis media caused by Streptococcus pneumoniae in healthy young children: a prospective observational study

scientific article published on 19 June 2018

Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children

article

Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older

artículo científico

Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia

artículo científico publicado en 2007

Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae

artículo científico publicado en 2014

Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain

artículo científico publicado en 2013

Evaluation of anatomic changes in young children with natural rotavirus infection: is intussusception biologically plausible?

artículo científico publicado en 2004

Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children

artículo científico publicado en 2004

Heptavalent Pneumococcal Conjugate Vaccine Immunogenicity and Safety in Japanese Infants : Primary and Booster Immunization Results ⬇️

artículo científico publicado el 1 de enero de 2011

Human capital gaps in vaccine development: an issue for global vaccine development and global health

artículo científico publicado en 2017

Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants

artículo científico publicado en 2005

Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus

artículo científico publicado en 2002

Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule

artículo científico publicado en 2013

Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine

artículo científico publicado en 2014

Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and Toddlers ⬇️

artículo científico publicado el 23 de agosto de 2010

Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Compared With 7-valent Pneumococcal Conjugate Vaccine Among Healthy Infants in China

artículo científico publicado en 2016

Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Coadministered with a Quadrivalent Influenza Vaccine in Adults 50 Years and Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine

artículo científico publicado en 2015

Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Given With DTaP Vaccine in Healthy Infants in Japan

scientific article published on 01 October 2015

Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine Administered in a 3 + 1 versus 2 + 1 Dose Schedule Among Infants in China

scientific article published on 01 November 2019

Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial

artículo científico publicado en 2010

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccines

artículo científico publicado en 2013

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in Mexico

artículo científico publicado en 2013

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine

artículo científico publicado en 2011

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years. An open-label trial

artículo científico publicado en 2014

Immunogenicity and safety of CRM197 conjugated 9-valent pneumococcal and meningococcal C combination vaccine in healthy infants ⬇️

artículo científico publicado el 4 de febrero de 2011

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination

artículo científico publicado en 2015

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults

artículo científico publicado en 2013

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

artículo científico publicado en 2013

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in India

artículo científico publicado en 2013

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan

artículo científico publicado en 2013

Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older

artículo científico publicado en 2016

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults

artículo científico publicado en 2015

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination

artículo científico publicado en 2015

Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal c

artículo científico publicado en 2011

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).

artículo científico publicado en 2017

Immunogenicity, safety and tolerability of 3 lots of 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in the United States

artículo científico publicado en 2013

Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label study

artículo científico publicado en 2015

Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease After Introduction Into Routine Pediatric Use

artículo científico publicado en 2020

Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older

artículo científico publicado en 2013

Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children

artículo científico publicado en 2009

Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations.

artículo científico publicado en 2018

Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain

artículo científico publicado en 2004

Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administration

artículo científico publicado en 2016

Multicenter surveillance of Streptococcus pneumoniae isolates from middle ear and mastoid cultures in the 13-valent pneumococcal conjugate vaccine era.

artículo científico publicado en 2015

Open-label trial of immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults ≥ 50 years of age in Mexico

artículo científico publicado en 2014

PCV13-vaccinated children still carrying PCV13 additional serotypes show similar carriage density to a control group of PCV7-vaccinated children

artículo científico publicado en 2017

Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag)

scientific article published on 24 December 2019

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults

scientific article published on 16 January 2019

Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults

artículo científico publicado en 2007

Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults

artículo científico publicado en 2019

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

preprint

Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults

scientific article published on 12 August 2020

Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine

artículo científico publicado en 2011

Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine

artículo científico publicado en 2014

Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.

artículo científico publicado en 2015

Post hoc analysis of a randomized double-blind trial of the correlation of functional and binding antibody responses elicited by 13-valent and 7-valent pneumococcal conjugate vaccines and association with nasopharyngeal colonization

artículo científico publicado en 2014

Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults

artículo científico publicado en 2018

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

artículo científico publicado en 2020

Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults

artículo científico publicado en 2012

S. aureus colonization in healthy Australian adults receiving an investigational S. aureus 3-antigen vaccine

scientific article published on 01 October 2019

SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies

artículo científico publicado en 2017

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine ⬇️

scientific article published on 10 December 2020

Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Children 6-17 Years of Age in India: An Open-label Trial

artículo científico publicado en 2017

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

artículo científico publicado en 2020

Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine in Adults 50 to 65 Years of Age in India: An Open-Label Trial.

artículo científico publicado en 2017

Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Manufactured With and Without Polysorbate 80 Given to Healthy Infants at 2, 3, 4 and 12 Months of Age

article

Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Pediatric Vaccinations in Canada

article

Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized ope

artículo científico publicado en 2014

Safety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses.

artículo científico publicado en 2008

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine

scientific article published on 01 May 2010

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers

artículo científico publicado en 2010

Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study

artículo científico

Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial

artículo científico publicado en 2020

Safety and tolerability of 13-valent pneumococcal conjugate vaccine in healthy Chinese adults, children and infants

artículo científico publicado en 2015

Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age.

artículo científico publicado en 2008

Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries

artículo científico publicado en 2013

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

artículo científico publicado en 2021

Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age

scientific article published on 27 July 2020

Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care

artículo científico publicado en 2006

Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study

artículo científico publicado en 2016

Safety, tolerability, and immunogenicity of a novel 4-antigen Staphylococcus aureus vaccine (SA4Ag) in healthy Japanese adults

artículo científico publicado en 2018

Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial

artículo científico publicado en 2016

Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany

artículo científico publicado en 2010

Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.

artículo científico

Serotype-specific immune responses to pneumococcal conjugate vaccine among children are significantly correlated by individual: Analysis of randomized controlled trial data

artículo científico publicado en 2017

Superior Relative Efficacy of Live Attenuated Influenza Vaccine Compared With Inactivated Influenza Vaccine in Young Children With Recurrent Respiratory Tract Infections

artículo científico publicado en 2006

The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial

artículo científico publicado en 2013

The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines

artículo científico publicado en 2007

The epidemiology of respiratory infections in children

scientific article published on 01 April 1995

The impact of the 13-valent pneumococcal conjugate vaccine on pneumococcal carriage in the Community Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Study

artículo científico publicado en 2018

The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans

artículo científico publicado en 2006

The role of live influenza vaccines in children

scientific article published on 01 May 2002

Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers

artículo científico publicado en 2005

Vaccination strategies for the prevention of meningococcal disease.

artículo científico publicado en 2018

Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine

artículo científico publicado en 2012

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda